SCHEMBL17068002

SCHEMBL17068002

Cc1ccc(/C=C/C(=O)/C=C/c2ccc(O)cc2)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 3/20 0.80
F3 P13726 2/20 0.80
HSD11B1 P28845 2/20 0.80
CYP2D6 P10635 1/20 0.80
CYP2C9 P11712 1/20 0.80
MAPT P10636 2/20 0.71
MAOB P27338 2/20 0.71
POLB P06746 1/20 0.71
MAOA P21397 1/20 0.71
RAB9A P51151 1/20 0.71
MMP1 P03956 1/20 0.65
MMP2 P08253 1/20 0.65
MMP9 P14780 1/20 0.65
FOS P01100 1/20 0.65
JUN P05412 1/20 0.65
GSK3B P49841 1/20 0.61
BACE1 P56817 1/20 0.61
TLR9 Q9NR96 1/20 0.61
CA12 O43570 3/20 0.59
CA1 P00915 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28606746 1.00 TYR (0.80) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL5598705 0.92 JUN (0.74) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL5598702 0.92 JUN (0.74) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL2198475 0.89 TYR (1.00) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL2146080 0.89 TYR (1.00) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL3580956 0.89 TYR (1.00) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL15290855 0.88 FOS (0.87) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL10631270 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL4370894 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9
SCHEMBL4371653 0.87 TYR (0.95) TYRF3HSD11B1CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540299-B2 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (HK) 2017-01-10 US disclosed
US-20160221907-A1 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (CN) 2016-08-04 US disclosed
US-9351946-B2 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (HK) 2016-05-31 US disclosed
US-20150250741-A1 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof HONG KONG BAPTIST UNIVERSITY (HK) 2015-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150250741-A1 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof TFEB, SQSTM1, ATG7 TYR 2186/4885F3 2784/4885HSD11B1 4798/4885
US-20160221907-A1 MTOR-independent activator of TFEB for autophagy enhancement and uses thereof TFEB, SQSTM1, ATG7 TYR 2186/4885F3 2784/4885HSD11B1 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.